| Literature DB >> 32464158 |
Bo Yuan1, Weixin Li2, Hanqing Liu3, Xin Cai1, Shuo Song3, Jia Zhao3, Xiaopeng Hu3, Zhiwen Li3, Yongxin Chen2, Kai Zhang4, Zhiyong Liu4, Jing Peng4, Cheng Wang2, Jianchun Wang5, Yawen An6.
Abstract
Self-reported depression has been observed in coronavirus disease-2019 (COVID-19) patients, infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), during discharge from the hospital. However, the cause of this self-reported depression during the convalescent period remains unclear. Here, we report the mental health status of 96 convalescent COVID-19 patients who were surveyed using an online questionnaire at the Shenzhen Samii Medical Center from March 2 to March 12, 2020 in Shenzhen, China. After obtaining their informed consent, we retrospectively analyzed the clinical characteristics of patients, including routine blood and biochemical data. The results suggested that patients with self-reported depression exhibited increased immune response, as indicated by increased white blood cell and neutrophil counts, as well as neutrophil-to-lymphocyte ratio. However, the mechanism linking self-reported depression to these cellular changes needs further study. In conclusion, self-reported depression occurred at an early stage in convalescent COVID-19 patients, and changes in immune function were apparent during short-term follow-up of these patients after discharge. Appropriate psychological interventions are necessary, and changes in immune function should be emphasized during long-term follow up of these patients.Entities:
Keywords: Blood routine analysis; Convalescent COVID-19 patients; Immunity response; Self-reported depression
Mesh:
Substances:
Year: 2020 PMID: 32464158 PMCID: PMC7247486 DOI: 10.1016/j.bbi.2020.05.062
Source DB: PubMed Journal: Brain Behav Immun ISSN: 0889-1591 Impact factor: 7.217
Epidemiological characteristics of 96 discharged patients survived from COVID-19 infections in Shenzhen city and their psychological states.
| Epidemiological characteristics | Normal (N = 54) | Self-reported Depression (N = 42) | F value | P value | |
|---|---|---|---|---|---|
| Potential effect of severity of initial infection (No., %) | Severe | 8/54 (14.8) | 5/42 (11.9) | 0.171 | 0.679 |
| Non-severe | 46/54 (85.2) | 37/42 (88.1) | |||
| Hospital stay, average (days) | 24.4 ± 6.7 | 24.8 ± 6.5 | 0.107 | 0.745 | |
| Questionnaire times since from twice negative virus test (days) | 6.2 ± 3.7 | 6.1 ± 3.9 | 0.864 | ||
| Age average (years) | 45.2 ± 13.2 | 49.6 ± 13.2 | 2.576 | 0.112 | |
| Age groups (No., %) | 18–45 | 29/54 (53.7) | 15/42 (35.7) | 3.080 | 0.079 |
| ≥46 | 25/54 (46.3) | 27/42 (64.3) | |||
| Gender groups (No., %) | Female | 27/54 (50.0) | 22/42 (52.4) | 0.054 | 0.817 |
| Male | 27/54 (50.0) | 20/42 (47.6) | |||
| Exposure to source within 14 days (No., %) | Wuhan exposure | 17/54 (31.5) | 17/42 (40.5) | 0.836 | 0.361 |
| No exposure | 37/54 (68.5) | 25/42 (59.5) | |||
| Comorbidities (No., %) | At least one | 22/54 (40.7) | 16/42 (38.1) | 0.069 | 0.793 |
| No comorbidity | 32/54 (59.3) | 26/42 (61.9) | |||
| Hypertension | 9/54 (16.7) | 6/42 (14.3) | 0.102 | 0.750 | |
| Diabetes | 6/54 (11.1) | 4/42 (9.5) | 0.064 | 0.801 | |
| cardiovascular disease | 4/54 (7.4) | 2/42 (4.8) | 0.282 | 0.595 | |
| Malignant tumor | 1/54 (1.9) | 1/42 (2.4) | 0.032 | 0.857 | |
| Liver disease | 5/54 (9.3) | 2/42 (4.8) | 0.707 | 0.400 | |
| Lung disease | 1/54 (1.9) | 0/42 (0) | 0.786 | 0.375 | |
| Other disease | 4/54 (7.4) | 7/42 (16.7) | 1.261 | 0.262 | |
| Positive of nucleic acid test after they dischargement (No., %) | Recurrence | 3/54 (5.6) | 4/42 (9.5) | 0.550 | 0.458 |
| Non-recurrence | 51/54 (94.4) | 38/42 (90.5) | |||
| Hospital stay (No., %) | ≤30 days | 45/54 (83.3) | 34/42 (81.0) | 0.092 | 0.762 |
| >30 days | 9/54 (16.7) | 8/42 (19.5) | |||
Continuous variables were analyzed using one-way ANOVA (Tamhane’s T2) test and the categorical variables were compared using Chi-square test (Monte Carlo Sig. T2).
Comparison of immune factors in COVID-19 discharged patients.
| Immune factors | Reference range | Normal group | Self-reported Depression | P value |
|---|---|---|---|---|
| WBC (109/L) | 3.5–9.5 | 6.0 ± 1.5 | 6.7 ± 1.5*↑ | 0.016 |
| NEUT (109/L) | 1.8–6.3 | 3.3 ± 0.9 | 4.1 ± 1.2***↑ | 0.000 |
| LYM (109/L) | 1.1–3.2 | 1.9 ± 0.6 | 1.8 ± 0.5 | 0.468 |
| MON (109/L) | 0.1–0.6 | 0.5 ± 0.2 | 0.5 ± 0.2 | 0.744 |
| EOS (109/L) | 0.02–0.52 | 0.1 ± 0.1 | 0.1 ± 0.1 | 0.568 |
| BASO (109/L) | 0–0.06 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.800 |
| Neutrophil-to-Lymphocyte Ratio (NLR) | / | 1.8 ± 0.6 | 2.4 ± 0.9***↑ | 0.000 |
| NEUT ratio (%) | 40–75 | 55.7 ± 6.4 | 61.0 ± 7.1***↑ | 0.000 |
| LYM ratio (%) | 20–50 | 32.3 ± 6.3 | 28.1 ± 6.7**↓ | 0.002 |
| BASO ratio (%) | 0–1 | 0.7 ± 0.3 | 0.6 ± 0.3 | 0.107 |
| EOS ratio (%) | 0.4–8.0 | 2.2 ± 1.5 | 2.1 ± 1.4 | 0.741 |
| MONO ratio (%) | 3–10 | 9.0 ± 2.4 | 8.2 ± 2.6 | 0.148 |
| HS-CRP (mg/dL) | 0–0.5 | 0.1 ± 0.1 | 0.2 ± 0.3*↑ | 0.035 |
| IL-6 (pg/mL) | 1.5–5000 | 56.1 ± 105.3 | 40.7 ± 65.6 | 0.518 |
Continuous variables were analyzed using one-way ANOVA (Tamhane’s T2) test. *P < 0.05, **P < 0.01, ***P < 0.001 vs normal group. The symbols ↓ and ↑ represented significantly higher or lower.